Table 1: Summary of patients’ characteristics, chemotherapy administered and best-response achieved.
|
Patient characteristics |
n |
% |
|
|
Patients with baseline PET scans (n=18) |
|
|
|
|
Gender |
Female |
10 |
56 |
|
Male |
8 |
44 |
|
|
Age (years) |
Median (range) |
63.8 (53.1-77.9) |
|
|
Location of primary tumour |
Head |
8 |
44 |
|
Neck |
3 |
17 |
|
|
Body |
4 |
22 |
|
|
Tail |
2 |
11 |
|
|
Not identifiable |
1 |
6 |
|
|
Size of primary tumour (cm) |
Median (range) |
4.95 (2.3-7) |
|
|
Stage |
Locally advanced |
3 |
17 |
|
Metastatic |
15 |
83 |
|
|
Sites of metastases |
Liver |
9 |
60 |
|
ECOG Performance Status |
0 |
4 |
22 |
|
1 |
11 |
61 |
|
|
2 |
3 |
17 |
|
|
Patients treated with chemotherapy (n =17) |
|
||
|
Chemotherapy regimen |
Gemcitabine single agent |
7 |
41 |
|
Gemcitabine + capecitabine |
4 |
24 |
|
|
Gemcitabine + nab-paclitaxel |
4 |
24 |
|
|
Gemcitabine + other drugs (TH-302 or vandetanib; clinical trials) |
2 |
11 |
|
|
Best radiological response to chemotherapy |
Partial response |
2 |
12 |
|
Stable disease |
7 |
41 |
|
|
Progressive disease |
3 |
18 |
|
|
Not assessed |
5 |
29 |
|
Eighteen patients were consented for the study, of which 17 started palliative chemotherapy. Of these, 7 had stable disease and 2 had partial response as assessed by RECIST v1.1.